Patent · US Active

RNAi modulation of ApoB and uses thereof

US7528118B2 · kind B2 · utility

15Cited by

1References

22Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Juergen Soutschek · Kasendorf, DE
Hans-Peter Vornlocher · Bayreuth, DE
Philipp Hadwiger · Kulmbach, DE
Sayda M. Elbashir · Cambridge, US

Key dates

Filing date	Sep 26, 2005
Grant date	May 5, 2009
Priority date	—
Expiry date	Jul 18, 2026

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/3515
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.